Posts

Padcev-Keytruda Combination Shows Strong Positive Data in Cisplatin-Eligible Muscle-Invasive Bladder Cancer

on

FDA’s One Trial Policy: Not a Revolution but a Potentially Risky Evolution

on

Uncertainty Looms Over Pharma's Legal Strategy as States Challenge New Vaccine Schedule

on

Boehringer Ingelheim's Hernexeos Receives Speedy FDA Approval for Lung Cancer Under CNPV Program

on

AI Tips and Prompts to Elevate Your 2026 Job Search

on

DeepHealth Achieves CE Mark for TechLive and Enables AWS Marketplace Deployment

on

Senate Hearing Criticizes FDA's Rare Disease Drug Review Process

on

Government of Canada and Partners Invest Over $41 Million in Cancer Prevention Research

on

Dexcom Appoints Google Executive Rick Osterloh to Board of Directors

on

DOJ Position on Hikma v. Amarin Skinny Label Case Before Supreme Court

on

Novartis Expands Radioligand Therapy Manufacturing with New German Facility

on

Gilead and Merck Advance Daily HIV Treatment Pills with Positive Late-Stage Data at CROI 2026

on

Lilly Tops Novo in Weight Loss Again, This Time on the Oral Front

on

PrecisionLife and Ovation Identify First Genetic Biomarkers to Predict GLP-1 Efficacy Response

on

Patient Death Triggers FDA Partial Clinical Hold on MacroGenics' LINNET Trial for Gynecologic Cancers

on

RFK Jr. Reshuffles HHS Leadership: Top Aides Exit, Key Promotions Announced Ahead of Midterms

on

Novo Nordisk Partners with Langer-Founded Vivtex on Oral Obesity Drugs in $2.1B Deal

on

Sarepta Therapeutics CEO Doug Ingram to Step Down by End of 2026 Amid Controversial Tenure

on

Rivus Pharmaceuticals Appoints Jorge Bartolome as Chief Executive Officer

on

Palvella Therapeutics Announces Pricing of Upsized Public Offering

on

Oncoinvent ASA Announces Second Half 2025 Results with Positive Radspherin Trial Data and Corporate Milestones

on

JCR Pharmaceuticals Announces Executive Appointments and Leadership Transition Effective April 1, 2026

on

Biopharma Bites: PhRMA Rebukes Trump's MFN Call, Pfizer Exercises Beam Base Editing Option, and Charles River Updates

on

Chemify and Sanacor Collaborate to Discover and Develop Small Molecule Therapies for Cardiometabolic Diseases

on

Lilly Bests Novo Again, Rare Disease Week Goes Regulatory, More CDC Leadership Upheaval

on

How LB Pharmaceuticals Rode Brutal Capital Markets to One of 2025's Most Successful IPOs

on

Novo Nordisk Announces 50% Wegovy List Price Cut to $675 Starting January 2027

on

Artiva Biotherapeutics Appoints Thad Huston as Chief Financial Officer

on

Pfizer Secures Exclusive China Rights to Sciwind's Approved GLP-1 Drug Ecnoglutide in $495M Deal

on

FDA Releases Draft Guidance on Plausible Mechanism Framework for Individualized Therapies in Ultra-Rare Diseases

on

Astellas and Vir Biotechnology Announce $1.7B Collaboration for VIR-5500 Prostate Cancer Drug, Including $240M Cash Upfront

on

AbbVie Invests $380 Million in Active Pharmaceutical Ingredient Manufacturing Expansion in North Chicago, Illinois

on

Gossamer Bio Stock Nosedives After Late-Stage Seralutinib Failure in PAH Trial

on

Novartis Presents Rhapsido (Remibrutinib) Data at AAAAI 2026, Highlighting Potential Beyond CSU

on

Roche Terminates Phase 2 SHIELD DMD Study for Satralizumab in Duchenne Bone Health

on

Novo Nordisk's CagriSema Underperforms Eli Lilly's Zepbound in Head-to-Head Phase 3 Obesity Trial

on

Spinogenix's SPG302 ALS Drug Shows Positive Phase IIa Results, Advances to Registrational Trial Amid Lingering Questions

on

Slate Medicines Launches with $130M Series A for Anti-PACAP Migraine Drug from China's DartsBio

on

Jake Leach Named Chair of AdvaMed's Diabetes Sector

on

Zelluna Receives UK MHRA and Ethics Approval to Initiate ZIMA-101 First-in-Human Clinical Trial

on

Biopharma Bites: FDA Reviews Roche and Teva NDAs, Candel Funding

on

Gilead Sciences Acquires Arcellx in $7.8 Billion Deal to Control CAR-T Cell Therapy

on

Vanda Pharmaceuticals Receives FDA Approval for Bysanti (Milsaperidone) for Schizophrenia and Bipolar I Disorder

on

Grail's Galleri Cancer Test Misses Primary Endpoint in NHS Trial, Shares Plunge Despite Positive Trends

on

Abivax Presents First Evidence of Anti-Fibrotic Activity for Obefazimod at ECCO 2026 Alongside IBD Clinical Data

on

'Just Agree to It': Pazdur Claims Pressure to Cosign FDA's Single-Trial Policy Shift

on

Verily Expands AI Health Platform Pre with New Datasets and Free Self-Serve Tools

on

Hims & Hers Acquires Australian Digital Health Company Eucalyptus for Up to $1.15 Billion

on

FDA Adopts Single Pivotal Trial as New Default for Drug Approvals

on